Impact of Financial Incentives
This trial will look at the impact of clinic-level financial incentives to improve provider communication and increase HPV vaccine uptake. Some clinics will receive communication training. Other clinics will receive the same training and a clinic-level financial incentive program with a monthly data feedback report to increase HPV vaccine uptake.
Conditions:
🦠 Human Papilloma Virus
🗓️ Study Start (Actual) 28 February 2023
🗓️ Primary Completion (Estimated) 31 July 2025
✅ Study Completion (Estimated) 31 August 2026
👥 Enrollment (Estimated) 34
🔬 Study Type INTERVENTIONAL
📊 Phase NA
Locations:
📍 Chapel Hill, North Carolina, United States

📋 Eligibility Criteria

Description

  • This trial will enroll clinics and intervene with clinical staff. We will use vaccination data from children to evaluate intervention effectiveness. We will not enroll children or interact with them directly.
  • Inclusion Criteria:

    • Clinics are eligible if they are a pediatric or family medicine clinic in North Carolina that in the past year had:
    • * less than 72% HPV vaccine initiation rate,
    • * greater than or equal to 50 patients ages 9-12
    • * greater than or equal to 2 HPV vaccine providers
    • * no clinic or provider-level financial incentive programs to increase system, clinic, or provider HPV vaccination rates among patients aged 9-12 in the past two years, and
    • * no HPV vaccine provider communication trainings in the past six months.
    • Children's medical records will be eligible to be included in the dataset if children:
    • * are between the ages of 9-12 years at baseline and
    • * are attributed to a participating clinic at 12- or 24-month follow-up.

    Exclusion Criteria:

    • Clinics are excluded if they:
    • * do not provide HPV vaccine to children ages 9-12
    • * have a specialty other than pediatrics or family medicine
    • * had an HPV vaccine-specific financial incentive program in the past two years
    • * had a formal HPV vaccine communication training in the past 6 months
    • * had an HPV initiation rate greater than 72$
    • * had fewer than 49 patients aged 9-12
    • * had 1 or fewer HPV vaccine providers
    • Children's medical records will not be eligible to be included in the dataset if children:
    • * are not between the ages of 9-12 years at baseline
    • * are not attributed to a participating clinic at 12- or 24-month follow-up
Ages Eligible for Study: 9 Years to 12 Years (CHILD)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 15 February 2023
  • First Submitted that Met QC Criteria 15 February 2023
  • First Posted 27 February 2023

Study Record Updates

  • Last Update Submitted that Met QC Criteria 8 March 2024
  • Last Update Posted 12 March 2024
  • Last Verified March 2024